Nontypeable Haemophilus influenzae (NTHI) is responsible for many acute and recurrent infections in children, such as otitis media.
Researchers characterize a component that stabilizes biofilms, a step toward learning ways to disrupt protection of harmful bacteria.
A new vaccine candidate has the potential to improve outcomes for patients with chronic, recurrent diseases, such as ear infections. Could this platform technology be an important key in solving the antibiotic resistance threat?
Patients with cystic fibrosis show transcriptomic changes after starting treatment with lumacaftor/ivacaftor.
Researchers from Nationwide Children’s Hospital use a collaborative approach to combat a serious health care threat.
Innovative prevention and treatment strategies bolstered by a deeper understanding of pathology may indicate a major shift on the horizon.
Rachael Hardison, PhD, shares recently published work from her graduate studies in the Mason and Justice Labs in The Research Institute at Nationwide Children’s.
